Jan 4, 2017Transperancy International report on Corruption in the Pharmaceutical Sector..
You can read the full report clicking from here
According to the report four overarching challenges derived from structural issues and anti-corruption policies across
the selected activities of the value chain have been identified. These are:
A lack of objective data and understanding of corruption inhibited by environmental
context, the complexity of issues in the sector and policy makers not viewing
corruption as an issue.
A weak legislative and regulatory framework because of poor investment, a lack of
oversight and national regulatory frameworks that are often decentralised and reliant
on self-regulation for key decision-point.
The potential for undue influence from companies due to a high degree of autonomy
over key decision points and unparalleled resources, on policy and regulation so
profit maximisation goes beyond ethical norms and negatively impacts health
outcomes and public health objectives.
A lack of leadership committed to anti-corruption efforts from all actors. National
leaders often only implement reforms after a crisis, with their inaction regularly
hindering other actors.